Klimek, Ludger
Brehler, Randolf
Hamelmann, Eckard
Kopp, Matthias
Ring, Johannes
Treudler, Regina
Jakob, Thilo
Worm, Margitta
Pfaar, Oliver
Article History
Received: 12 June 2018
Accepted: 24 September 2018
First Online: 13 May 2019
Conflict of interest
: L. Klimek has received research funds from the following companies: ALK-Abelló, Denmark; Allergopharma, Germany; Bionorica, Germany; Biomay, Austria; Boehringer Ingelheim, Germany; Circassia, USA; Stallergenes, France; HAL, The Netherlands; Allergy Therapeutics/Bencard, Great Britain/Germany; Hartington, Spain; Lofarma, Italy and MEDA, Sweden; MSD, USA; Novartis, Switzerland; LETI, Spain; ROXALL, Germany; GlaxoSmithKline, Great Britain; Cytos, Switzerland and Curalogic, Denmark. In addition, L. Klimek is a consultant for AllergyTherapeutics/Bencard, UK/Germany; HAL, The Netherlands; MEDA, Germany; and Boehringer Ingelheim, Germany. R. Brehler has received research funding from the following companies: Allergopharma, Bencard, and Biotech Tools, as well as Genentech, LETI, Novartis, and Circassia. He has also been a speaker for ALK-Abelló, Allergopharma, Almirall, Astra Zeneca, Bencard, the German Society for the Promotion of Dermatological Research and Training (Gesellschaft zur Förderung der Dermatologischen Forschung und Fortbildung), the German Society for Information and Organization (Gesellschaft für Information und Organisation), as well as GlaxoSmithKline, Dr. Pfleger, HAL, LETI, MedUpdate, Merck, Novartis, The Otorhinolaryngology Association (Oto-Rhino-Laryngologischer Verein), Pierre Fabre, Pohl Boskamp, Stallergenes, and Thermo-Fischer. R. Brehler has worked as a consultant for: Allergopharma, Bencard, HAL, LETI, and Novartis. Eckard Hamelmann has received research funding from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF), North Rhine-Westphalia State Ministry of Research (Landesforschungsministerium Nordrhein-Westfalen) and the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG). He has also given lectures and been a consultant for Allergy Therapeutics/Bencard, Great Britain/Germany; ALK-Abelló, Denmark; Allergopharma, Germany; Boehringer Ingelheim, Germany; GlaxoSmithKline, Great Britain; HAL Allergy, The Netherlands; LETI, Spain; Lofarma, Italy; Novartis, Switzerland, and Stallergenes, France. E. Hamelmann declares that he has no competing interests. M. Kopp received fees from ALK-Abelló, Allergopharma, LETI, and Novartis, as well as from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Infectopharm during the period of this study. J. Ring has served on advisory boards for ALK-Abelló, Allergopharma, Bencard, HAL, and Novartis. R. Treudler states that she received fees from ALK-Abelló and LETI during the period of this study. Over and above this study, she has received fees from Sanofi Aventis and Novartis. T. Jakob has received the following grants and funding for projects other than the work submitted here: research grants and fees from ALK-Abelló, Germany; fees and nonfinancial support from Bencard/Allergy Therapeutics, Germany; research grants, fees, and nonfinancial support from Thermo Fisher Scientific, Sweden, as well as fees from Stallergenes, Germany; research grants, fees, and nonfinancial support from Allergopharma, Germany, and research grants and fees from Novartis, Germany. T. Jakob has also received fees from Springer Nature, as well as nonfinancial support from the German Society for Allergology and Clinical Immunology (Deutsche Gesellschaft für Allergie und klinische Immunologie). M. Worm reports fees for advisory boards and lecture activities from Allergopharma GmbH & Co. KG, ALKAbelló Arzneimittel GmbH, Meda Pharma GmbH & Co. KG, HAL Allergie GmbH, Stallergenes GmbH, Bencard Allergie GmbH, LETI Pharma GmbH, outside the submitted work. O. Pfaar reports grants and personal fees from ALK-Abelló, grants and personal fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal fees from Lofarma, grants from Biomay, grants from Nuvo, grants from Circassia, grants and personal fees from ASIT Biotech Tools S.A., grants and personal fees from Laboratorios LETI/LETI Pharma, personal fees from Novartis Pharma, personal fees from MEDA Pharma, grants and personal fees from Anergis S.A., personal fees from Mobile Chamber Experts (a GA2LEN Partner), personal fees from Pohl-Boskamp, personal fees from Indoor Biotechnologies, grants from Glaxo Smith Kline, personal fees from Astellas Pharma Global, outside the submitted work.